Full-Time

Maintenance Technician 4

Posted on 9/14/2026

Resilience

Resilience

1,001-5,000 employees

Cyber insurance paired with risk-quantifying SaaS

Compensation Overview

CA$28.50 - CA$43/hr

+ Annual cash bonus + RRSP/DPSP company match

Mississauga, ON, Canada

In Person

Weekday afternoon and weekend continental night shifts are expected; schedules may change based on business needs.

Associate's, Certification

Category
General Maintenance & Repair (1)
Required Skills
HVAC
GMP
PLC

Get referred to Resilience

See people who can refer or advise you

Requirements
  • Progressive and substantial hands-on industrial maintenance experience, preferably in a pharmaceutical or food manufacturing environment.
  • Demonstrated troubleshooting capability across mechanical systems, including pumps, motors, mechanical seals, pneumatic systems, HVAC and mechanical equipment, bearings, belts, couplings, and alignment.
  • Demonstrated troubleshooting capability across electrical systems, including single- and three-phase systems, variable frequency drives, transformers, relays and overloads, and control circuits.
  • Ability to read electrical schematics and use a multimeter and other electrical test equipment.
  • Demonstrated troubleshooting capability across instrumentation and controls, including programmable logic controller input/output troubleshooting, basic programmable logic controller diagnostics, sensors, transmitters and switches, 4–20 mA and 0–10 V signals, proximity and photoelectric sensors, control panels, and human-machine interface troubleshooting.
  • Strong organizational and communication skills.
  • Ability to respond flexibly to demanding operational situations.
  • Ability to manage multiple concurrent and shifting priorities and independently determine work sequence and technical approach within the maintenance discipline.
  • Ability to stand for extended periods, crouch or squat, lift up to 20 kg (44 lbs), and work in cleanroom environments with appropriate gowning requirements, including use of a respirator as required.
Responsibilities
  • Maintain, test, evaluate, and inspect critical equipment and systems to provide safe and reliable facility infrastructure, including lubrication, inspection, cleaning, and functional testing.
  • Conduct scheduled maintenance and predictive checks on production equipment, including pumps, autoclaves, part washers, filling and capping machines, exhaust fans, Clean Utility systems, and heating, ventilation, and air-conditioning systems.
  • Determine maintenance priorities based on equipment history, condition monitoring, and production schedules; drive work-order prioritization and scheduling of preventive and corrective tasks.
  • Monitor and respond to system failures, alarms, and abnormal site conditions by taking appropriate preventive and corrective actions.
  • Diagnose and repair mechanical and control-system issues to minimize downtime and maintain continuous operation of the current good manufacturing practice manufacturing facility.
  • Apply internal procedures, industry standards, and manufacturer specifications to inspect, diagnose, and troubleshoot production, measuring, and test equipment.
  • Resolve issues independently and escalate issues that fall outside established procedures.
  • Inspect third-party repairs and rebuilds for adherence to requirements and quality of work.
  • Identify recurring failure modes and propose and implement improvements to equipment performance, reliability, and safety.
  • Lead or participate in projects to upgrade machinery or processes.
  • Document maintenance, repair, preventive maintenance, and modification activities accurately in work orders and maintenance records.
  • Complete work orders in accordance with current good manufacturing practice requirements and standard operating procedures.
  • Ensure maintenance activities comply with current good manufacturing practice requirements, company policies, safety standards, and standard operating procedures.
  • Follow safety protocols, perform risk assessments, and support initiatives promoting a safe working environment, including compliance with environmental, health, and safety regulations.
Desired Qualifications
  • A 2-year diploma or certificate in Electrical, Electromechanical, Instrumentation, Automation, or Mechanical Engineering Technology, or an equivalent combination of education and experience.
  • At least 5 years of industrial maintenance experience, preferably in a pharmaceutical or food manufacturing environment.
  • Industrial Millwright (433A) license or equivalent working experience in a maintenance field.
  • Industrial Electrician (442A) license.
  • Experience with processing, filling, and packaging equipment.
  • Experience in a current good manufacturing practice environment and calibration awareness.
  • Working knowledge of safety procedures, lockout/tagout, and electrical safety.
  • Ability to work from piping and instrumentation diagrams, electrical drawings, schematics, and equipment manuals.

Resilience provides cyber insurance to mid-market and large enterprises and licenses the Resilience Solution, a SaaS platform that translates a company’s security posture into a financially oriented action plan used for underwriting and risk management. The platform quantifies technology controls, estimates ROI of security investments, and informs insurance pricing. It runs a risk operations center with continuous threat intelligence and in-house claims handling, emphasizing third-party risk. Goal: move beyond risk transfer by actively improving client security and reducing losses across sectors such as manufacturing, agriculture, and healthcare.

Company Size

1,001-5,000

Company Stage

Growth Equity (Venture Capital)

Total Funding

$3.2B

Headquarters

San Diego, California

Founded

2020

Get referred to Resilience

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • The July 30, 2026 Lilly deal adds $750 million and 400 Cincinnati jobs.
  • Full KwikPen operations start in early 2027, expanding exposure to obesity and diabetes demand.
  • Oak Hill Advisors funded up to $825 million in 2025, extending liquidity runway.

What critics are saying

  • Resilience's growth depends heavily on Lilly, making 2027 contract renewals existential.
  • The 2025 OHA financing and lease cleanup show a capital-hungry business with underused sites.
  • Moving headquarters from San Diego to Blue Ash cuts 200 jobs and can damage recruiting.

What makes Resilience unique

  • Resilience combines CDMO manufacturing with device assembly, packaging, and cold-storage in one network.
  • Blue Ash, West Chester, and Toronto anchor a regulated North American manufacturing platform.
  • Lilly has trusted Resilience since 2023, producing over 150 million doses.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Unlimited Paid Time Off

Paid Holidays

Family Planning Benefits

Fertility Treatment Support

Tuition Reimbursement

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

0%
BioSpace
Jul 31st, 2026
Lilly and Resilience invest $750M in diabetes and obesity drug device supply.

Lilly and Resilience invest $750M in diabetes and obesity drug device supply. July 31, 2026 | The investment will expand Resilience's U.S. capacity to make the KwikPen device Eli Lilly uses to deliver its injectable diabetes and obesity medicines. Eli Lilly is expanding its partnership with service provider Resilience, with the pair committing $750 million to U.S. drug manufacturing capacity. The partners are using the cash to bolster Resilience's operations in the Cincinnati region. Through the investment, Resilience will significantly increase U.S. production of Lilly's KwikPen injectable device for diabetes and obesity medicines. The contract development and manufacturing organization (CDMO) is preparing the site for expansion with the aim of starting full operations early next year. In February, Lilly won FDA approval for Zepbound in a multidose KwikPen device. The product includes four doses of the GLP-1/GIP receptor agonist, providing a month of treatment for obesity or overweight in one device. Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or lower-dose Zepbound from other injectable incretin therapies. May 13, 2026 Resilience expects the KwikPen capacity expansion to create at least 400 jobs in the Cincinnati area. The addition of the new roles will bring the number of jobs created by Resilience in Ohio - where the CDMO has two sites around Cincinnati - up to 1,400. Resilience also has plants in Philadelphia and Toronto. The spend on the Ohio site continues Resilience's rapid rise. Launched in 2020 with more than $800 million from backers including Arch Venture Partners and 8VC, the CDMO went on to form pacts with companies including AstraZeneca, Sanofi and Takeda while raising almost $2.5 billion across two financing rounds, a debt deal and a loan from the U.S. Department of Defense. Resilience has used the money to add manufacturing capacity. The CDMO expanded a facility in West Chester, Ohio, in 2023; invested $225 million in a Cincinnati plant in 2024; and grew at two Ohio locations in 2025. In June, Resilience moved its corporate headquarters from San Diego to Blue Ash, Ohio, a northern suburb of Cincinnati. The company has partnered with JobsOhio to help staff the sites. The CDMO began working with Lilly in 2023. Resilience's archives lack a press release naming Lilly as a partner in 2023, although that year the CDMO did disclose a 10-year biomanufacturing alliance with an unnamed "leading pharmaceutical company." At the time, Resilience predicted the deal would support record revenues. Resilience has made more than 150 million doses of medicines for Lilly. Eli Lilly's latest manufacturing expansion will support production of obesity blockbusters and next-gen assets, while the new Lilly Lebanon Advanced Therapies site will take experimental genetic medicines from research to commercialization. May 8, 2026

Hospital Management
Jul 31st, 2026
Resilience and Lilly to increase US medicines production with $750m investment.

Resilience and Lilly to increase US medicines production with $750m investment. The investment will support Resilience's advanced manufacturing operations in Cincinnati. Resilience and Eli Lilly and Company have expanded their partnership with a joint $750m investment to increase the production of Lilly's KwikPen injectable device in Ohio, aiming to strengthen the supply of diabetes and obesity medicines in the US. The investment will support the expansion of Resilience's advanced manufacturing operations in the Cincinnati region and create at least 400 new jobs. With this initiative, the total number of jobs generated by Resilience across its Ohio sites will exceed 1,400. Preparation for the site expansion has commenced, and complete operations are projected to begin in early 2027. The expanded collaboration builds upon a strategic partnership between the two firms first formed in 2023. This initiative is in response to growing patient demand for injectable treatments for diabetes and obesity in the US. Resilience president and CEO William Marth said: "Hospital Management is proud of what Hospital Management has built together with Lilly and this new expansion as Hospital Management scale production of complex medicines in Ohio. "Our investment reflects our long-term commitment to building one of the largest and most advanced sterile injectable and device assembly and packaging operations in the US, and demonstrates how trusted partnerships, operational excellence, and disciplined execution can strengthen America's medicine supply." Lilly executive vice-president and manufacturing operations president Edgardo Hernandez said: "As demand for our medicines continues to increase, scaling complex manufacturing programmes requires proven technical capability, an uncompromising commitment to quality, and the ability to deliver consistently over time." The partnership has so far resulted in the production of more than 150 million doses of medicines for US patients in vial and pre-filled syringe formats. Resilience operates two facilities in the region, employing nearly 1,000 staff across various functions. The location in Blue Ash, Ohio, was recently established as Resilience's global headquarters. The company's partnerships with REDI Cincinnati, JobsOhio, and Ohio Life Sciences have also supported workforce development efforts in the Cincinnati area. Prior to this, Eli Lilly and Company entered an agreement with Innovent Biologics for the commercialisation of Verzenios (abemaciclib) in mainland China. Give your business an edge with its leading industry insights.

TechStartups
Jul 30th, 2026
Venture Capital & Startup Funding Roundup, July 30, 2026: Bessemer Venture Partners, G2 Venture Partners, ICONIQ Growth, Kleiner Perkins, Lightspeed & More - Tech Startups

Tech investors are doubling down on the infrastructure underpinning today’s AI boom – from satellites in orbit to power-hungry data centers on Earth. The day’s largest deals span space tech, clean energy and AI-infused enterprise platforms, signaling where capital is flowing: into hardware-heavy, mission-critical fields. Satcom manufacturer K2 Space ($500M Series D) and thermal-battery startup Antora Energy ($550M

WTWH Media
Jul 30th, 2026
Resilience, Lilly invest $750M in pharma, KwikPen manufacturing.

Resilience, Lilly invest $750M in pharma, KwikPen manufacturing. Resilience announced today that it expanded its strategic partnership with Eli Lilly (NYSE:LLY) to increase medicine production in the U.S. The Cincinnati-based CDMO and the pharmaceutical giant first struck a partnership in 2023. Now, with $750 million invested, the companies are expanding Resilience's advanced pharmaceutical manufacturing operations in Ohio. Now, Resilience's production in that region includes the Lilly KwikPen injectable device for delivering GLP-1 therapies for diabetes and obesity. Adding KwikPen production also creates at least 400 new high-skilled jobs. That brings the total Resilience-created jobs in Ohio to more than 1,400 across its facilities. Resilience and Lilly have preparation underway for the campus expansion, with full operations slated to begin in early 2027. This adds to the partnership that has, to date, produced more than 150 million doses of medicine for patients in the U.S. in vial and pre-filled syringe formats. Together, the companies offer one of the nation's largest sterile injectable manufacturing operations, they said in a news release. Commentary from Resilience and Lilly officials. William S. Marth, president and CEO of Resilience, said: "We are proud of what we have built together with Lilly and this new expansion as we scale production of complex medicines in Ohio. Our investment reflects our long-term commitment to building one of the largest and most advanced sterile injectable and device assembly and packaging operations in the United States, and demonstrates how trusted partnerships, operational excellence, and disciplined execution can strengthen America's medicine supply." Edgardo Hernandez, Lilly's EVP and president, Manufacturing Operations, said: "As demand for our medicines continues to increase, scaling complex manufacturing programs requires proven technical capability, an uncompromising commitment to quality, and the ability to deliver consistently over time. Today's announcement highlights Resilience's role as a strong partner to Lilly in strengthening domestic supply of high-demand treatments."

AMS Group, LLC
Jul 30th, 2026
Lilly, Resilience to invest $750 million in US drug manufacturing expansion.

Lilly, Resilience to invest $750 million in US drug manufacturing expansion. July 30 (Reuters) - Drugmaker Eli Lilly and privately held contract manufacturer Resilience will invest $750 million to expand pharmaceutical manufacturing capacity in the U.S. and strengthen the domestic medicine supply chain, Resilience said on Thursday. Global drugmakers have been ramping up U.S. manufacturing since last year and stockpiling inventory as President Donald Trump's administration moves to impose 100% tariffs on branded drugs unless companies cut prices or make medicines domestically. - Resilience said the investment will increase the production of critical medicines and create 400 new high-skilled jobs in the Cincinnati, Ohio region. - The company's manufacturing operations in the region will now include Lilly's KwikPen injectable device for treating diabetes and obesity, it added. - The multi-year manufacturing partnership between Lilly and Resilience, which began in 2023, has already produced more than 150 million doses of medicines for U.S. patients in vial and pre-filled syringe formats, according to Resilience. - Lilly's manufacturing head Edgardo Hernandez said the partnership reflects the drugmaker's efforts to meet rising demand for its medicines. - Lilly's U.S. capital expansion commitments since 2020 total more than $55 billion and it plans to break ground on several of its recently announced U.S. manufacturing sites this year. (Reporting by Christy Santhosh in Bengaluru; Editing by Jonathan Ananda)